Targeted Therapy Improves Pancreatic Cancer Survival
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to‑treat cancer.
The study demonstrates that targeting KRAS‑driven pancreatic cancer can extend survival and improve quality of life, providing hope for patients with previously treated metastatic pancreatic adenocarcinoma.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.